Stockreport

Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies [Seeking Alpha]

Kyverna Therapeutics, Inc.  (KYTX) 
PDF Phase 2 data for mivocabtagene autoleucel shows strong efficacy and favorable safety in autoimmune indications, supporting late-stage advancement. A recent $100 milli [Read more]